Pfizer Investing $500 Million in North Carolina Gene Therapy Facility, Adding 300 Jobs

Pfizer Investing $500 Million in North Carolina Gene Therapy Facility, Adding 300 Jobs

Pfizer announced it is putting an additional $500 million into the construction of its gene therapy manufacturing site in Sanford, North Carolina. It is planned to support the company’s investment in gene therapy research and development, much...

Read more
Yaoyanshe Raises $42 Million for On-Line CRO/CMO Services

Yaoyanshe Raises $42 Million for On-Line CRO/CMO Services

Yaoyanshe, a Shanghai on-line AI-based CRO/CMO, raised $42 million in a C funding round led by Eastern Bell Capital and Sequoia China. Founded in 2015, Yaoyanshe offers Trial.Link, a repository of China clinical trial information that connects...

Read more
Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.

Alligator Bioscience Signs Antibody Agreement for Greater China with Biotheus Inc.

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China. Under the license...

Read more
Abbisko Approved to Start US Trial of CSF-1R Immunotherapy

Abbisko Approved to Start US Trial of CSF-1R Immunotherapy

Abbisko Therapeutics, a Shanghai clinical-stage biopharma, received approval to begin a US Phase I trial for ABSK021, a small molecule CSF-1R inhibitor. By inhibiting CSF-1R, ABSK021 is expected to reprogram tumor-associated macrophages (TAMs)...

Read more
Kintor Pharma Starts CDMO Cooperation with CMAB for ALK-1 Cancer Drug

Kintor Pharma Starts CDMO Cooperation with CMAB for ALK-1 Cancer Drug

Suzhou Kintor Pharmaceuticals signed a cooperation agreement with CMAB Biopharma (Suzhou), a biologics CDMO, to develop and manufacture Kintor’s ALK-1 mAb. Kintor in-licensed global rights to the candidate from Pfizer, which previously...

Read more
China News Weekly 124 – China Unveils Reform to Help Firms Borrow More Cheaply

China News Weekly 124 – China Unveils Reform to Help Firms Borrow More Cheaply

Click here to find more details This is NAI’s new China News Weekly. We will be covering the latest Chinese foreign investment trends every week. To continue to receive our China News Weekly, please click the button below to subscribe.

Read more
China’s LHHC Signs Up Vancouver’s Enlighta to Market AI Early Test for Cancer

China’s LHHC Signs Up Vancouver’s Enlighta to Market AI Early Test for Cancer

LHHC Medical Technology, a China AI company, announced a global cooperation with Vancouver’s Enlighta to market LHHC’s early cancer detection test. The “No Cancer” technology combines LHHC’s AI data models and...

Read more
Shenzhen Xpect Vision Closes $14 Million Round for New Imaging Tech

Shenzhen Xpect Vision Closes $14 Million Round for New Imaging Tech

Shenzhen Xpect Vision Technology closed a $14 million B financing to support development of its new imaging technologies. Founded in 2015, Xpect considers itself a leader in photon-counting X-ray imaging along with other new technologies such as...

Read more
CMS Acquires China Rights to Seven Generic Drugs from India’s Sun Pharma

CMS Acquires China Rights to Seven Generic Drugs from India’s Sun Pharma

Shenzhen’s China Medical System acquired China rights to seven generic drugs from India’s Sun Pharma. The seven drugs were not identified, but Sun Pharma said they have China market revenues of $1 billion annually. Two months ago, CMS...

Read more
India’s Natco Joins the March to China’s Market by Indian Pharmas

India’s Natco Joins the March to China’s Market by Indian Pharmas

India’s Natco Pharma, a company that specializes in complex generics, plans to build up its business in China, taking advantage of China’s speeded-up approval process to register products that are already approved elsewhere. Natco has...

Read more
Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange

Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange

Nanjing Frontier Biotechnologies was approved to stage a $285 million IPO on the Shanghai STAR Exchange. Frontier has a China approved treatment for HIV, and it is developing another HIV treatment that it in-licensed from the Rockefeller...

Read more
Do NOT follow this link or you will be banned from the site!